edoxaban

DE and Johnson & Johnson's Xarelto, and Bristol and Pfizer's Eliquis -- as well as a late pipeline product call edoxaban from Daiichi-Sankyo .

unknown title 2011

DE, Johnson & Johnson's Xarelto, and a late pipeline product called edoxaban from Japan's Daiichi Sankyo .

unknown title 2011

Previous trials have shown that edoxaban, which is being developed by Daiichi Sankyo, achieves dose-dependent anticoagulation over a range of doses, with no significant dose-related increase in bleeding.

Health News from Medical News Today 2009

Apixaban, from Bristol-Myers Squibb Co. and Pfizer is also ahead of betrixaban, and edoxaban from Daiichi Sankyo Co. of Japan is in late-stage studies.

Merck Returns Betrixaban Rights Amid Pipeline Review Jonathan D. Rockoff 2011

Also, Daiichi Sankyo Co. is developing a drug called edoxaban.

Drug to Prevent Stroke Is Approved Jennifer Corbett Dooren 2010

Daiichi Sankyo Co. has developed another Factor Xa inhibitor, edoxaban, which has been approved in Japan.

Anticlot Drug From J&J, Bayer Advances Peter Loftus 2011

Also, Daiichi Sankyo Co. is developing a drug called edoxaban.

Blood Drug Gets Nod 2010

Daiichi Sankyo recently launched a similar of study of edoxaban.

Race On to Prevent Clots 2010

The Phase III study, Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE AF-TIMI 48), began enrolling patients in late 2008 and is comparing edoxaban with warfarin (target INR 2-3) for the prevention of stroke and systemic embolic events (SEE) among patients with atrial fibrillation.

FinanzNachrichten.de: Aktuelle Nachrichten 2010

"Based on what we've seen in Phase II and other trials, edoxaban shows promise as an agent to help fulfill the need for treatment options that are safe, effective and more convenient than the current standard of care, which requires extensive monitoring, careful dose adjusting and may have the potential for various drug and food interactions."

FinanzNachrichten.de: Aktuelle Nachrichten 2010